An interventional study of Carotid Artery Stenting in Carotid Artery Stenosis, Carotid Artery Stenosis Asymptomatic and Atherosclerosis, sponsored by Suzhou Zenith Vascular SciTech Limited. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Suzhou Zenith Vascular SciTech Limited · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Carotid Stenosis with a site in China — 33 open to participants now, 37 under way, 1 of them phase 3. Carotid Stenosis · China.
Among the 71 studies in Carotid Stenosis with a site in China, this one is the 15th largest by planned enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2026, is one of 26 with no phase, reaches primary completion later than 30 of the 36 other live ones, and was the 71st registered.
364 studies on the registry are indexed under Carotid Stenosis; 85 are open to participants now.
Browse Carotid Stenosis studies →33 of the 71 studies in Carotid Stenosis with a site in China are open now. Recruiting first, the newest first:
The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital · Sites in China
Ages 30–80
Beijing Tiantan Hospital · Sites in China
Ages 18+
General Hospital of Shenyang Military Region · Sites in China
Ages 40+
Chinese PLA General Hospital · Sites in China
Ages 10–90
Beijing Anzhen Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 60 Carotid Stenosis studies recruiting now, 38 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 208 is above the median of 103 across 189 interventional studies indexed under Carotid Stenosis.
Median enrollment 178 across the 37 interventional studies, 200 across the 34 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 71 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Suzhou Zenith Vascular SciTech Limited as lead sponsor.
Suzhou Zenith Vascular SciTech Limited has 1 study filed under Carotid Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Carotid Stenosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07004673Ruijin Hospital18F FDG and 68Ga FAPI PET/MR Imaging of Carotid Artery Plaque Vulnerability: A Clinical Study in Carotid Artery Plaque Patients | 2026-12-31 |
| NCT05134246Xuanwu Hospital, BeijingCarotid Revascularization for Radiation Induced Carotid Artery Stenosis | 2026-12-31 |
| NCT07036991Changhai HospitalA Cohort Study Comparing PCSK9 Inhibitor Plus Statin With Statin Monotherapy for Carotid Artery Stenosis | 2027-06-01 |
| NCT07247864Beijing Anzhen HospitalBalloon Guide Catheter Combined With Filter Protection for Carotid Artery Stenting | 2027-09-01 |
| NCT07412249General Hospital of Shenyang Military RegionRemote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 71 studies in Carotid Stenosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, single-group, target value clinical trial planning to enroll 208 eligible subjects. Participants will be treated with the investigational carotid artery stent system and followed up at discharge, 30 days, 6 months, and 12 months postoperatively to evaluate the safety and efficacy of the device for endovascular treatment of carotid artery stenosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General Inclusion Criteria (all must be satisfied):
CEA High-Risk Inclusion Criteria (at least one criterion must be met):
Clinical High-Risk Factors:
Anatomic High-Risk Factors:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Carotid Artery Stenting
All participants will undergo carotid artery stenting (CAS).
Incidence of In-Stent Restenosis (ISR)
Restenosis is defined as ≥50% diameter stenosis occurring within the stent or within 5 mm of the proximal or distal stent edge of the target carotid artery, as assessed by carotid duplex ultrasound (DUS).
Time frame: through study completion, an average of 1 year
Incidence of Major Adverse Events (MAE)
Major adverse events (MAE) are defined as the composite incidence of: (1) death, stroke (ischemic or hemorrhagic), or myocardial infarction (MI) occurring within 30 days after the procedure; and (2) death or ipsilateral ischemic stroke of the target vessel occurring from 31 to 365 days after the procedure.
Time frame: through study completion, an average of 1 year
Device Success Rate
Defined as the percentage of enrolled subjects in whom device success is achieved. Device success is defined as successful implantation (including delivery, deployment, and expansion) of the stent covering the target lesion, with successful retrieval of the delivery system.
Time frame: Intraoperative
Procedural Success Rate
Defined as the percentage of enrolled subjects in whom procedural success is achieved. Procedural success is defined as successful implantation of the stent, with post-procedure angiography demonstrating ≤30% residual stenosis at the target lesion, and freedom from major adverse events (MAE; defined as all-cause death, stroke, or myocardial infarction) prior to hospital discharge.
Time frame: Perioperative
Incidence of In-Stent Restenosis (ISR)
Defined as the percentage of enrolled subjects who develop ISR at 6 months post-procedure. ISR is defined as restenosis within the stent or within 5 mm proximal or distal to the stent edge of the target carotid artery, as assessed by carotid duplex ultrasound (DUS), with DUS criteria indicating ≥50% diameter stenosis.
Time frame: 6 months
Incidence of Target Lesion Revascularization (TLR)
The percentage of enrolled subjects who undergo TLR within 30 days, at 6 months, and at 12 months post-procedure. TLR is defined as any repeat revascularization (including any surgical or percutaneous intervention) of the target lesion after the initial index procedure.
Time frame: 30 days,6 months,12 months
Incidence of Ipsilateral Ischemic Stroke
Defined as the percentage of enrolled subjects who experience an ipsilateral ischemic stroke at 6 months and 12 months post-procedure. Ipsilateral ischemic stroke is defined as an ischemic stroke occurring in the cerebral hemisphere supplied by the target vessel (the carotid artery treated during the index procedure).
Time frame: 6 months,12 months
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: through study completion, an average of 1 year
Incidence of Device Deficiencies
Time frame: through study completion, an average of 1 year
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
Of 61 interventional studies with no phase under Carotid Stenosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 50. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.